거세저항성 전립선암 치료제 개발 동향

• 영문명: Trends in the Development of Castration-resistant Prostate Cancer Treatment
• 발행기관: 대한약학회
• 저자명: 김지원(Jiwon Kim) 이준녕(Jun Nyung Lee) 하윤석(Yun-Sok Ha) 권태균(Tae Gyun Kwon) 이상규(Sangkyu Lee)
• 간행물 정보: 『약학회지』제64권 제4호(2020년), 243~249쪽, 전체 7쪽
• 주제분류: 의약학 > 기타의약학
• 파일형태: PDF
• 발행일자: 2020.08.30

영문 초록

Prostate cancer is one of the most common male cancer. It tends to be known as “mild cancer” due to its high five-year survival rate. However, some patients develop castration-resistant prostate cancer (CRPC) during androgen deprivation therapy (ADT) treatment, with high metastasis and poor prognosis. In addition to conventional ADT treatments, specific treatments are implemented for CRPC. There are four second-generation anti-androgen drugs, taxane chemotherapy, and immunotherapy using vaccines and monoclonal antibodies. This review paper outlines the mechanism of prostate cancer leading to CRPC and reviews the standard treatment of CRPC. It also summarized the trends of anticancer drugs under clinical trials to obtain CRPC as an additional indication.

목차

서 론(Introduction)

결 론(Conclusion)

Conflict of Interest

References

키워드

castration-resistant prostate cancer anti-androgens prostate cancer chemotherapy